Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color Jun. 07, 2025 6:30 PM ET Regeneron Pharmaceuticals ...

Four out of 10 eczema patients struggle with sleep, and they may not volunteer that information unless you ask.

Unfortunately, treating atopic dermatitis on the hands and feet has historically been difficult and there have been no Phase 3 trials evaluating a biologic in this population of patients,” said ...

Children with moderate/more extensive atopic dermatitis treated with ruxolitinib cream achieved significant disease control ...

Regeneron Pharmaceuticals and Sanofi have announced promising outcomes from the open-label Phase IV DISCOVER trial of Dupixent (dupilumab) in treating moderate-to-severe atopic dermatitis (AD) in ...

Atopic dermatitis is a chronic skin condition driven by type 2 inflammation, often presenting with more pronounced symptoms and skin lesions in individuals with skin of color. Dupixent was ...

Moderate-to-Severe Atopic Dermatitis: Optimizing Care Across Specialties This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

REGN banks on Dupixent and Eylea HD gains to offset Eylea's decline while oncology wins strengthen its diversified pipeline.

Apogee Therapeutics has shared positive 16-week results from a mid-stage study of its investigational anti-IL-13 antibody in ...

Please provide your email address to receive an email when new articles are posted on . Patients with hand and foot atopic dermatitis (HFAD) endure significant discomfort, impaired quality of life ...

News provided by Regeneron Pharmaceuticals, Inc. Jun 07, 2025, 6:30 PM ET Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved 75% or ...